Claims
- 1. A method for reducing alcohol desire or dependency, comprising the steps of:
administering a therapeutically effective amount of an amino acid chelate to a human having symptoms of alcohol desire or dependency, said amino acid chelate comprising a naturally occurring amino acid ligand and a metal selected from the group consisting of copper, zinc, and manganese, and wherein the amino acid to metal molar ratio is from 1:1 to 4:1.
- 2. A method as in claim 1, wherein the metal is copper.
- 3. A method as in claim 1, wherein the metal is zinc.
- 4. A method as in claim 1, wherein the metal is manganese.
- 5. A method as in claim 1, further comprising coadministering to the human a second amino acid chelate that is different than the amino acid chelate, said second amino acid chelate also comprising a naturally occurring amino acid ligand and a metal selected from the group consisting of copper, zinc, and manganese, and wherein the second amino acid chelate has an amino acid to metal molar ratio from 1:1 to 4:1.
- 6. A method as in claim 1, further comprising coadministering to the human a therapeutically effective amount of thiamine or a thiamine-containing composition.
- 7. A method as in claim 6, wherein the thiamine-containing composition is coadministered and comprises thiamine or a thiamine phosphate molecule which is chelated or complexed to a nutritionally relevant metal.
- 8. A method as in claim 1, further comprising coadministering to the human a therapeutically effective amount of a metal carnitine chelate, said metal carnitine chelate comprising a metal selected from the group consisting of copper, zinc, or manganese, and wherein the carnitine to metal molar ratio is from 1:1 to 2:1.
- 9. A method as in claim 1, wherein the amino acid is selected from the group consisting of glycine, cystine, cysteine, arginine, histidine, lysine, glutamic acid, and combinations thereof.
- 10. A method as in claim 5, further comprising coadministering to the human a third amino acid chelate that is different than the amino acid chelate and the second amino acid chelate, said third amino acid chelate also comprising a naturally occurring amino acid ligand and a metal selected from the group consisting of copper, zinc, and manganese, and wherein the third amino acid chelate has an amino acid to metal molar ratio from 1:1 to 4:1.
- 11. A method for reducing alcohol desire or dependency, comprising the steps of:
administering a therapeutically effective amount of a composition to a human having symptoms of alcohol desire or dependency, said composition comprising a naturally occurring amino acid chelated to a nutritionally relevant metal, said composition further comprising thiamine complexed to the nutritionally relevant metal.
- 12. A method as in claim 11, wherein the nutritionally relevant metal is selected from the group consisting of calcium, magnesium, copper, zinc, and manganese.
- 13. A method as in claim 11, wherein the thiamine is a thiamine phosphate, and the thiamine phosphate is completed at its phosphate moiety to the nutritionally relevant metal.
- 14. A method as in claim 11, wherein the thiamine is complexed at the N1 position of its pyrimidine ring to the nutritionally relevant metal.
- 15. A method as in claim 11, further comprising coadministering to the human a therapeutically effective amount of an amino acid chelate comprising a naturally occurring amino acid ligand and a metal selected from the group consisting of copper, zinc, and manganese, wherein the amino acid to metal molar ratio is from 1:1 to 4:1.
- 16. A method as in claim 11, further comprising coadministering to the human a therapeutically effective amount of thiamine or a second thiamine-containing composition.
- 17. A method as in claim 1, further comprising coadministering to the human a therapeutically effective amount of a carnitine ligand chelated to a metal selected from the group consisting of copper, zinc, or manganese, wherein the carnitine to metal molar ratio is from 1:1 to 2:1.
- 18. A method as in claim 11, wherein the naturally occurring amino acid is selected from the group consisting of glycine, cystine, cysteine, arginine, histidine, lysine, glutamic acid, and combinations thereof.
- 19. A method as in claim 11, wherein a coordination number of the metal is fully satisfied.
- 20. A method as in claim 11, further comprising an ancillary molecule complexed or coordinated to the metal.
- 21. A method for reducing alcohol desire or dependency, comprising the steps of:
administering a therapeutically effective amount of a metal carnitine chelate to a human having symptoms of alcohol desire or dependency, said metal carnitine chelate comprising a metal selected from the group consisting of copper, zinc, or manganese, and wherein the carnitine to metal molar ratio is from 1:1 to 2:1.
- 22. A method as in claim 21, wherein the metal is copper.
- 23. A method as in claim 21, wherein the metal is zinc.
- 24. A method as in claim 21, wherein the metal is manganese.
- 25. A method as in claim 21, further comprising coadministering to the human an amino acid chelate, said amino acid chelate comprising a naturally occurring amino acid ligand and a metal selected from the group consisting of copper, zinc, and manganese, and wherein the second amino acid to metal molar ratio is from 1:1 to 4:1.
- 26. A method as in claim 21, further comprising coadministering to the human a therapeutically effective amount of thiamine or a thiamine-containing composition.
- 27. A method as in claim 26, wherein the thiamine-containing composition is coadministered and comprises thiamine or a thiamine phosphate molecule which is chelated or complexed to a nutritionally relevant metal.
- 28. A method for reducing alcohol desire or dependency, comprising the steps of:
administering a therapeutically effective amount of a metal thiamine chelate to a human having symptoms of alcohol desire or dependency, wherein the metal is chelated to thiamine through a π-cloud of an aromatic ring.
- 29. A method as in claim 28, wherein a naturally occurring amino acid is also chelated to the metal.
- 30. A composition for reducing alcohol dependency, comprising a metal carnitine chelate, said metal being selected from the group consisting of copper, zinc, or manganese, wherein the carnitine to metal molar ratio is from 1:1 to 2:1.
- 31. A composition as in claim 30, further comprising an amino acid chelate admixed or blended with the metal carnitine chelate, said amino acid chelate comprising a naturally occurring amino acid ligand and a metal selected from the group consisting of copper, zinc, and manganese, and wherein the amino acid to metal molar ratio is from 1:1 to 4:1.
- 32. A composition as in claim 30, further comprising thiamine or a thiamine-containing composition admixed or blended with the metal carnitine chelate.
- 33. A thiamine-complexed metal amino acid chelate composition for reducing alcohol dependency, comprising a naturally occurring amino acid chelated to a nutritionally relevant metal, said composition further comprising thiamine complexed to the nutritionally relevant metal.
- 34. A composition as in claim 33, wherein the thiamine is a thiamine phosphate, and the thiamine phosphate is complexed to the metal at its phosphate moiety.
- 35. A composition as in claim 33, wherein the thiamine is complexed to the metal at the N1 position of its pyrimidine ring.
- 36. A composition as in claim 33, wherein the nutritionally relevant metal is selected from the group consisting of calcium, magnesium, copper, zinc, and manganese.
- 37. A composition as in claim 33, wherein the naturally occurring amino acid is selected from the group consisting of glycine, cystine, cysteine, arginine, histidine, lysine, glutamic acid, and combinations thereof.
- 38. A composition as in claim 33, wherein the amino acid to metal molar ratio is about 1:1.
- 39. A composition as in claim 33, wherein the thiamine to metal molar ratio is about 1:1.
- 40. A composition as in claim 33, wherein the thiamine to amino acid to metal molar ratio is about 1:1:1.
- 41. A composition as in claim 33, wherein the amino acid to metal molar ratio is about 2:1.
- 42. A composition as in claim 33, wherein the thiamine to metal molar ratio is about 2:1.
- 43. A composition as in claim 33, wherein a coordination number of the metal is fully satisfied.
- 44. A composition as in claim 33, further comprising an ancillary molecule complexed or coordinated to the metal.
- 45. A composition as in claim 44, wherein the ancillary molecule is selected from the group consisting of water, acids, chloride, and nitrates.
- 46. A composition as in claim 33, wherein the thiamine is a thiamine phosphate selected from the group consisting of thiamine mono-phosphate, thiamine di-phosphate, and thiamine tri-phosphate.
- 47. A composition for reducing alcohol dependency in humans, comprising a particulate blend of:
a) a first amino acid chelate comprising a naturally occurring amino acid and a metal selected from the group consisting of copper, zinc, and manganese; and b) a second amino acid chelate comprising a second naturally occurring amino acid and a second metal selected from the group consisting of copper, zinc, and manganese, wherein the first amino acid chelate and the second amino acid chelate each having an amino acid to metal molar ratio from 1:1 to 4:1, and wherein the first amino acid chelate and the second amino acid chelate each have a different metal.
- 48. A composition as in claim 47, wherein the first amino acid chelate is a copper amino acid chelate, the second amino acid chelate is a zinc amino acid chelate, and wherein the particulate blend further comprises a third amino acid chelate comprising a naturally occurring amino acid and manganese, said third amino acid chelate having an amino acid to metal molar ratio from 1:1 to 4:1.
Parent Case Info
[0001] The present application claims the benefit of U.S. Provisional Application No. 60/334,051 filed on Nov. 28, 2001, which is incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60334051 |
Nov 2001 |
US |